ITGI wins $1m stent order for clinical trial

Hospitals in the company's own clinical trial will pay full price for the stents.

ITGI Medical Ltd. (TASE:ITGI) has received a $1 million order for 1,000 stents by 20 hospitals in Israel and Europe. The use of the stents will be part of a large clinical trial that the company is conducting for marketing purposes, but the hospitals will pay full price for them.

The trial is due to last three years, although preliminary results are expected in 2011 and further results in 2012. Good results from the trial could give ITGI's competitive position a strong boost. The company's Over-and-Under heterologous tissue covered stent already has EU CE Mark Certification, and the company has applied for US Food and Drug Administration (FDA) approval.

ITGI's share price rose 0.5% today to NIS 0.64, giving a market cap of NIS 41 million.

Published by Globes [online], Israel business news - www.globes-online.com - on February 18, 2010

© Copyright of Globes Publisher Itonut (1983) Ltd. 2010

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Yaron Daniely Replacing Ritalin

Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.

Twitter Facebook Linkedin RSS Newsletters